Even though Corcept Therapeutics Incorporated (NASDAQ:CORT) has fallen by 4.4% over the past week , insiders who sold US$1.8m worth of stock over the past year have had less luck. Given that the average selling price of US$20.16 is still lower than the current share price, insiders would probably have been better off keeping their shares.

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

View our latest analysis for Corcept Therapeutics

Corcept Therapeutics Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider sale was by the Chief Business Officer & Secretary, Gary Robb, for US$1.1m worth of shares, at about US$20.89 per share. That means that even when the share price was below the current price of US$25.96, an insider wanted to cash in some shares. When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. This single sale was just 35% of Gary Robb's stake. The only individual insider seller over the last year was Gary Robb.

Gary Robb divested 90.00k shares over the last 12 months at an average price of US$20.16. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).

Insider Ownership Of Corcept Therapeutics

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Corcept Therapeutics insiders own about US$306m worth of shares (which is 11% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

What Might The Insider Transactions At Corcept Therapeutics Tell Us?

The fact that there have been no Corcept Therapeutics insider transactions recently certainly doesn't bother us. It's great to see high levels of insider ownership, but looking back over the last year, we don't gain confidence from the Corcept Therapeutics insiders selling. Therefore, you should definitely take a look at this FREE report showing analyst forecasts for Corcept Therapeutics.

Of course Corcept Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.